Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

The Catalan blood products company has received a $21 million grant from the Michael J. Fox Foundation (MJFF) for Parkinson's ...

At the same time, Grifols has formed a strategic alliance with Haier in the market for plasma products, particularly albumin, and diagnostics. It has been involved in a series of acquisitions in ...

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes ...

Immune globulin (human) is under clinical development by Grifols and currently in Phase II for Coronavirus Disease 2019 (COVID-19).

That is below Grifols' current share price of around ... based pharmaceuticals and other products like blood transfusion diagnostics, which is tax-domiciled in Ireland and has a significant ...

As global markets navigate a mixed economic landscape marked by declining consumer confidence and fluctuating indices, technology stocks continue to capture attention with their potential for high ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...